Close

Marc Lipsitch

Professor

Education

Affiliations

Projects

MIDAS CENTER FOR COMMUNICABLE DISEASE DYNAMICS

National Institutes of Health, National Institute of General Medical Sciences
People: Laura White, Ted Cohen, William Hanage, Rene Niehus, Ben Cowling, Tyler Brown, Joseph Wu, Mauricio Santillana Guzman, Joseph Lewnard, Aimee Taylor, Pablo Martinez de Salazar, Lerato Magosi, Edward Goldstein, Christine Tedijanto, Tigist Menkir, Sze Man Leung, Hsiao-Han Chang, Caroline Buckee, Pamela Martinez, Marc Lipsitch
2009 – 2020

Read More »

Papers

Goldstein E, Olesen SW, Karaca Z, Steiner CA, Viboud C, Lipsitch M. (2019). Levels of outpatient prescribing for four major antibiotic classes and rates of septicemia hospitalization in adults in different US states - a statistical analysis. BMC Public Health, 19(1)

MacFadden DR, Fisman DN, Hanage WP, Lipsitch M. (2019). The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase-producing Escherichia coli. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 69(1)

Lipsitch M, Santillana M. (2019). Enhancing Situational Awareness to Prevent Infectious Disease Outbreaks from Becoming Catastrophic. Current topics in microbiology and immunology

Yang A, Cai F, Lipsitch M. (2019). Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage. BMC infectious diseases, 19(1)

Lipsitch M. (2019). Challenges of Vaccine Effectiveness and Waning Studies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68(10)

Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. (2019). THE AUTHORS REPLY. American journal of epidemiology, 188(4)

Eyal N, Kimmelman J, Holtzman LG, Lipsitch M. (2019). Regulating impact on bystanders in clinical trials: An unsettled frontier. Clinical trials (London, England), 16(5)

Georgieva M, Buckee CO, Lipsitch M. (2019). Models of immune selection for multi-locus antigenic diversity of pathogens. Nature reviews. Immunology, 19(1)

Goldstein E, Finelli L, O'Halloran A, Liu P, Karaca Z, Steiner CA, Viboud C, Lipsitch M. (2019). Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children, Including Children Diagnosed with Asthma. Epidemiology (Cambridge, Mass.), 30(6)

Lipsitch M, Shaman J. (2019). Comment on: 'Antibiotic footprint' as a communication tool to aid reduction of antibiotic consumption. The Journal of antimicrobial chemotherapy, 74(11)

Goldstein E, MacFadden DR, Karaca Z, Steiner CA, Viboud C, Lipsitch M. (2019). Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. International journal of antimicrobial agents, 54(1)

Kahn R, Hitchings M, Wang R, Bellan SE, Lipsitch M. (2019). Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection. American journal of epidemiology, 188(2)

Hitchings MDT, Coldiron ME, Grais RF, Lipsitch M. (2019). Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis. PLoS neglected tropical diseases, 13(3)

Lipsitch M, Li LM, Patterson S, Trammel J, Juergens C, Gruber WC, Scott DA, Dagan R. (2018). Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. Vaccine, 36(4)

Sevilla JP, Bloom DE, Cadarette D, Jit M, Lipsitch M. (2018). Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proceedings of the National Academy of Sciences of the United States of America, 115(51)

Relman DA, Lipsitch M. (2018). Microbiome as a tool and a target in the effort to address antimicrobial resistance. Proceedings of the National Academy of Sciences of the United States of America, 115(51)

Tedijanto C, Olesen SW, Grad YH, Lipsitch M. (2018). Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. Proceedings of the National Academy of Sciences of the United States of America, 115(51)

Goldstein E, Nguyen HH, Liu P, Viboud C, Steiner CA, Worby CJ, Lipsitch M. (2018). On the Relative Role of Different Age Groups During Epidemics Associated With Respiratory Syncytial Virus. The Journal of infectious diseases, 217(2)

Lipsitch M. (2018). Why Do Exceptionally Dangerous Gain-of-Function Experiments in Influenza?. Methods in molecular biology (Clifton, N.J.)

Goldstein E, Worby CJ, Lipsitch M. (2018). On the Role of Different Age Groups and Pertussis Vaccines During the 2012 Outbreak in Wisconsin. Open forum infectious diseases, 5(5)

Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. (2018). Measurement of Vaccine Direct Effects Under the Test-Negative Design. American journal of epidemiology, 187(12)

Kahn R, Hitchings M, Bellan S, Lipsitch M. (2018). Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials. Clinical trials (London, England), 15(2)

Atkins KE, Lipsitch M. (2018). Can antibiotic resistance be reduced by vaccinating against respiratory disease?. The Lancet. Respiratory medicine, 6(11)

Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M. (2017). Simulations for designing and interpreting intervention trials in infectious diseases. BMC medicine, 15(1)

Lipsitch M. (2017). If a Global Catastrophic Biological Risk Materializes, at What Stage Will We Recognize It?. Health security, 15(4)

Croucher NJ, Campo JJ, Le TQ, Liang X, Bentley SD, Hanage WP, Lipsitch M. (2017). Diverse evolutionary patterns of pneumococcal antigens identified by pangenome-wide immunological screening. Proceedings of the National Academy of Sciences of the United States of America, 114(3)

Eyal N, Lipsitch M. (2017). Vaccine testing for emerging infections: the case for individual randomisation. Journal of medical ethics, 43(9)

Lipsitch M, Evans NG, Cotton-Barratt O. (2017). Underprotection of Unpredictable Statistical Lives Compared to Predictable Ones. Risk analysis : an official publication of the Society for Risk Analysis, 37(5)

Goldstein E, Pitzer VE, O'Hagan JJ, Lipsitch M. (2017). Temporally Varying Relative Risks for Infectious Diseases: Implications for Infectious Disease Control. Epidemiology (Cambridge, Mass.), 28(1)

Chang HH, Huber RG, Bond PJ, Grad YH, Camerini D, Maurer-Stroh S, Lipsitch M. (2017). Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bulletin of the World Health Organization, 95(7)

Grad YH, Lipsitch M. (2017). Reply to Allan-Blitz and Klausner. The Journal of infectious diseases, 215(3)

Cobey S, Baskerville EB, Colijn C, Hanage W, Fraser C, Lipsitch M. (2017). Host population structure and treatment frequency maintain balancing selection on drug resistance. Journal of the Royal Society, Interface, 14(133)

McCormick AW, Abuelezam NN, Fussell T, Seage GR 3rd., Lipsitch M. (2017). Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences. Epidemics

Azarian T, Grant LR, Georgieva M, Hammitt LL, Reid R, Bentley SD, Goldblatt D, Santosham M, Weatherholtz R, Burbidge P, Goklish N, Thompson CM, Hanage WP, O'Brien KL, Lipsitch M. (2017). Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing Isolates. The Journal of infectious diseases, 215(5)

Grad YH, Harris SR, Kirkcaldy RD, Green AG, Marks DS, Bentley SD, Trees D, Lipsitch M. (2016). Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000-2013. The Journal of infectious diseases, 214(10)

Lipsitch M. (2016). Comment on "Gain-of-Function Research and the Relevance to Clinical Practice". The Journal of infectious diseases, 214(8)

Chang HH, Dordel J, Donker T, Worby CJ, Feil EJ, Hanage WP, Bentley SD, Huang SS, Lipsitch M. (2016). Identifying the effect of patient sharing on between-hospital genetic differentiation of methicillin-resistant Staphylococcus aureus. Genome medicine, 8(1)

Wu JT, Peak CM, Leung GM, Lipsitch M. (2016). Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet (London, England), 388(10062)

Lipsitch M, Cowling BJ. (2016). Zika vaccine trials. Science (New York, N.Y.), 353(6304)

Lipsitch M, Siber GR. (2016). How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?. MBio, 7(3)

Lipsitch M, Jha A, Simonsen L. (2016). Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. International journal of epidemiology, 45(6)

Lipsitch M, Inglesby TV. (2015). Reply to "Studies on influenza virus transmission between ferrets: the public health risks revisited". MBio, 6(1)

Lipsitch M, Esvelt K, Inglesby T. (2015). Calls for caution in genome engineering should be a model for similar dialogue on pandemic pathogen research. Annals of internal medicine, 163(10)

Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, Ferguson NM, Garske T, Mills HL, Riley S, Van Kerkhove MD, Hernán MA. (2015). Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. PLoS neglected tropical diseases, 9(7)

Trzciński K, Li Y, Weinberger DM, Thompson CM, Cordy D, Bessolo A, Malley R, Lipsitch M. (2015). Effect of Serotype on Pneumococcal Competition in a Mouse Colonization Model. MBio, 6(5)

Lipsitch M, Inglesby TV. (2015). Erratum for lipsitch and inglesby, moratorium on research intended to create novel potential pandemic pathogens. MBio, 6(1)

Li Y, Croucher NJ, Thompson CM, Trzciński K, Hanage WP, Lipsitch M. (2015). Identification of pneumococcal colonization determinants in the stringent response pathway facilitated by genomic diversity. BMC Genomics

Lipsitch M, Eyal N, Halloran ME, Hernán MA, Longini IM, Perencevich EN, Grais RF. (2015). Vaccine testing. Ebola and beyond. Science (New York, N.Y.), 348(6230)

Chang HH, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. (2015). Origin and proliferation of multiple-drug resistance in bacterial pathogens. Microbiology and molecular biology reviews : MMBR, 79(1)

Goldstein E, Greene SK, Olson DR, Hanage WP, Lipsitch M. (2015). Estimating the hospitalization burden associated with influenza and respiratory syncytial virus in New York City, 2003-2011. Influenza and other respiratory viruses, 9(5)

Jacobs JH, Viboud C, Tchetgen ET, Schwartz J, Steiner C, Simonsen L, Lipsitch M. (2014). The association of meningococcal disease with influenza in the United States, 1989-2009. PLoS One, 9(9)

Li Y, Thompson CM, Lipsitch M. (2014). A modified Janus cassette (Sweet Janus) to improve allelic replacement efficiency by high-stringency negative selection in Streptococcus pneumoniae. PLoS One, 9(6)

Fisman DN, Leung GM, Lipsitch M. (2014). Nuanced risk assessment for emerging infectious diseases. Lancet (London, England), 383(9913)

Grad YH, Lipsitch M. (2014). Epidemiologic data and pathogen genome sequences: a powerful synergy for public health. Genome biology, 15(11)

Lipsitch M. (2014). Can limited scientific value of potential pandemic pathogen experiments justify the risks?. MBio, 5(5)

Lipsitch M, Inglesby TV. (2014). Moratorium on research intended to create novel potential pandemic pathogens. MBio, 5(6)

Worby CJ, Chang HH, Hanage WP, Lipsitch M. (2014). The distribution of pairwise genetic distances: a tool for investigating disease transmission. Genetics, 198(4)

Grad YH, Kirkcaldy RD, Trees D, Dordel J, Harris SR, Goldstein E, Weinstock H, Parkhill J, Hanage WP, Bentley S, Lipsitch M. (2014). Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. The Lancet. Infectious diseases, 14(3)

Lipsitch M, Galvani AP. (2014). Ethical alternatives to experiments with novel potential pandemic pathogens. PLoS medicine, 11(5)

Ascioglu S, Samore MH, Lipsitch M. (2014). A new approach to the analysis of antibiotic resistance data from hospitals. Microbial drug resistance (Larchmont, N.Y.), 20(6)

Shaman J, Lipsitch M. (2013). The El Nino-Southern Oscillation (ENSO)-pandemic influenza connection: coincident or causal?. Proceedings of the National Academy of Sciences of the United States of America

Joice R, Lipsitch M. (2013). Targeting imperfect vaccines against drug-resistance determinants: a strategy for countering the rise of drug resistance. PLoS One, 8(7)

Link-Gelles R, Thomas A, Lynfield R, Petit S, Schaffner W, Harrison L, Farley MM, Aragon D, Nicols M, Kirley PD, Zansky S, Jorgensen J, Juni BA, Jackson D, Moore MR, Lipsitch M. (2013). Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. The Journal of infectious diseases, 208(8)

Lipsitch M. (2013). Avian influenza: Ferret H7N9 flu model questioned. Nature, 501(7465)

Li Y, Thompson CM, Trzciński K, Lipsitch M. (2013). Within-host selection is limited by an effective population of Streptococcus pneumoniae during nasopharyngeal colonization. Infection and immunity, 81(12)

Li Y, Weinberger DM, Thompson CM, Trzciński K, Lipsitch M. (2013). Surface charge of Streptococcus pneumoniae predicts serotype distribution. Infection and immunity, 81(12)

Shaman J, Karspeck A, Yang W, Tamerius J, Lipsitch M. (2013). Real-time influenza forecasts during the 2012-2013 season. Nature communications

Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, Bentley SD, Hanage WP, Lipsitch M. (2013). Population genomics of post-vaccine changes in pneumococcal epidemiology. Nature genetics, 45(6)

Cobey S, Lipsitch M. (2013). Pathogen diversity and hidden regimes of apparent competition. The American naturalist, 181(1)

Lipsitch M, Hernán MA. (2013). Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57(9)

Ke W, Huang SS, Hudson LO, Elkins KR, Nguyen CC, Spratt BG, Murphy CR, Avery TR, Lipsitch M. (2012). Patient sharing and population genetic structure of methicillin-resistant Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America, 109(17)

Pitzer VE, Burgner D, Viboud C, Simonsen L, Andreasen V, Steiner CA, Lipsitch M. (2012). Modelling seasonal variations in the age and incidence of Kawasaki disease to explore possible infectious aetiologies. Proceedings. Biological sciences, 279(1739)

Lipsitch M, Plotkin JB, Simonsen L, Bloom B. (2012). Evolution, safety, and highly pathogenic influenza viruses. Science (New York, N.Y.), 336(6088)

Cobey S, Lipsitch M. (2012). Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science (New York, N.Y.), 335(6074)

O'Hagan JJ, Hernán MA, Walensky RP, Lipsitch M. (2012). Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS (London, England), 26(2)

Lipsitch M, Bloom BR. (2012). Rethinking biosafety in research on potential pandemic pathogens. MBio, 3(5)

Li Y, Gierahn T, Thompson CM, Trzciński K, Ford CB, Croucher N, Gouveia P, Flechtner JB, Malley R, Lipsitch M. (2012). Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS pathogens, 8(11)

Jacobs JH, Archer BN, Baker MG, Cowling BJ, Heffernan RT, Mercer G, Uez O, Hanshaoworakul W, Viboud C, Schwartz J, Tchetgen Tchetgen E, Lipsitch M. (2012). Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age. PLoS One, 7(8)

Goldstein E, Viboud C, Charu V, Lipsitch M. (2012). Improving the estimation of influenza-related mortality over a seasonal baseline. Epidemiology (Cambridge, Mass.), 23(6)

Goldstein E, Kirkcaldy RD, Reshef D, Berman S, Weinstock H, Sabeti P, Del Rio C, Hall G, Hook EW, Lipsitch M. (2012). Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States. Emerging infectious diseases, 18(8)

Lipsitch M, Abdullahi O, DʼAmour A, Xie W, Weinberger DM, Tchetgen Tchetgen E, Scott JA. (2012). Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model. Epidemiology (Cambridge, Mass.), 23(4)

Grad YH, Miller JC, Lipsitch M. (2012). Cholera modeling: challenges to quantitative analysis and predicting the impact of interventions. Epidemiology (Cambridge, Mass.), 23(4)

Goldstein E, Cowling BJ, Aiello AE, Takahashi S, King G, Lu Y, Lipsitch M. (2011). Estimating incidence curves of several infections using symptom surveillance data. PLoS One, 6(8)

Shaman J, Goldstein E, Lipsitch M. (2011). Absolute humidity and pandemic versus epidemic influenza. American journal of epidemiology, 173(2)

Shaman J, Jeon CY, Giovannucci E, Lipsitch M. (2011). Shortcomings of vitamin D-based model simulations of seasonal influenza. PLoS One, 6(6)

Weinberger DM, Malley R, Lipsitch M. (2011). Serotype replacement in disease after pneumococcal vaccination. Lancet (London, England), 378(9807)

Weinberger DM, Harboe ZB, Flasche S, Scott JA, Lipsitch M. (2011). Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology (Cambridge, Mass.), 22(2)

Goldstein E, Cobey S, Takahashi S, Miller JC, Lipsitch M. (2011). Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. PLoS medicine, 8(7)

Hernán MA, Lipsitch M. (2011). Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 53(3)

Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd SC, . (2011). Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. Biosecurity and bioterrorism : biodefense strategy, practice, and science, 9(2)

Shaman J, Pitzer VE, Viboud C, Grenfell BT, Lipsitch M. (2010). Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS biology, 8(2)

Goldstein E, Cowling BJ, O'Hagan JJ, Danon L, Fang VJ, Hagy A, Miller JC, Reshef D, Robins J, Biedrzycki P, Lipsitch M. (2010). Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. BMC infectious diseases

Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Rückinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, O'Brien KL, Scott JA, Lipsitch M. (2010). Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51(6)

Wallinga J, van Boven M, Lipsitch M. (2010). Optimizing infectious disease interventions during an emerging epidemic. Proceedings of the National Academy of Sciences of the United States of America, 107(2)

Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R, Lipsitch M. (2010). What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?. Journal of the Royal Society, Interface, 7(47)

Miller JC, Danon L, O'Hagan JJ, Goldstein E, Lajous M, Lipsitch M. (2010). Student behavior during a school closure caused by pandemic influenza A/H1N1. PLoS One, 5(5)

Goldstein E, Miller JC, O'Hagan JJ, Lipsitch M. (2010). Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic. Influenza and other respiratory viruses, 4(2)

Lipsitch M, Tchetgen Tchetgen E, Cohen T. (2010). Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology (Cambridge, Mass.), 21(3)

Lajous M, Danon L, López-Ridaura R, Astley CM, Miller JC, Dowell SF, O'Hagan JJ, Goldstein E, Lipsitch M. (2010). Mobile messaging as surveillance tool during pandemic (H1N1) 2009, Mexico. Emerging infectious diseases, 16(9)

Goldstein E, Lipsitch M. (2009). Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United States. PLoS currents

Goldstein E, Lipsitch M. (2009). H1N1 vaccination and adults with underlying health conditions in the US. PLoS currents

Goldstein E, Dushoff J, Ma J, Plotkin JB, Earn DJ, Lipsitch M. (2009). Reconstructing influenza incidence by deconvolution of daily mortality time series. Proceedings of the National Academy of Sciences of the United States of America, 106(51)

Goldstein E, Miller JC, O'Hagan J, Lipsitch M. (2009). Predispensing of antivirals to high-risk individuals in an influenza pandemic. PLoS currents

Pitzer VE, Lipsitch M. (2009). Exploring the relationship between incidence and the average age of infection during seasonal epidemics. Journal of theoretical biology, 260(2)

Lipsitch M, Viboud C. (2009). Influenza seasonality: lifting the fog. Proceedings of the National Academy of Sciences of the United States of America, 106(10)

Lipsitch M, Lajous M, O'Hagan JJ, Cohen T, Miller JC, Goldstein E, Danon L, Wallinga J, Riley S, Dowell SF, Reed C, McCarron M. (2009). Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. PLoS One, 4(9)

Lipsitch M, Riley S, Cauchemez S, Ghani AC, Ferguson NM. (2009). Managing and reducing uncertainty in an emerging influenza pandemic. The New England journal of medicine, 361(2)

Lipsitch M, Hayden FG, Cowling BJ, Leung GM. (2009). How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. Lancet (London, England), 374(9696)

Klugman KP, Astley CM, Lipsitch M. (2009). Time from illness onset to death, 1918 influenza and pneumococcal pneumonia. Emerging infectious diseases, 15(2)

Presanis AM, De Angelis D, , Hagy A, Reed C, Riley S, Cooper BS, Finelli L, Biedrzycki P, Lipsitch M. (2009). The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS medicine, 6(12)

Weinberger DM, Trzciński K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. (2009). Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS pathogens, 5(6)

Lipsitch M, Colijn C, Cohen T, Hanage WP, Fraser C. (2009). No coexistence for free: neutral null models for multistrain pathogens. Epidemics, 1(1)

Cohen T, Lipsitch M. (2008). Too little of a good thing: a paradox of moderate infection control. Epidemiology (Cambridge, Mass.), 19(4)

Trzciński K, Thompson CM, Srivastava A, Basset A, Malley R, Lipsitch M. (2008). Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infection and immunity, 76(6)

Regev-Yochay G, Malley R, Rubinstein E, Raz M, Dagan R, Lipsitch M. (2008). In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized children. Journal of clinical microbiology, 46(2)

Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. (2008). Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. The Journal of infectious diseases, 197(11)

Lipsitch M, O'Hagan JJ. (2007). Patterns of antigenic diversity and the mechanisms that maintain them. Journal of the Royal Society, Interface, 4(16)

Lipsitch M, O'Neill K, Cordy D, Bugalter B, Trzcinski K, Thompson CM, Goldstein R, Pelton S, Huot H, Bouchet V, Reid R, Santosham M, O'Brien KL. (2007). Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. The Journal of infectious diseases, 196(8)

Hatchett RJ, Mecher CE, Lipsitch M. (2007). Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proceedings of the National Academy of Sciences of the United States of America, 104(18)

Pitzer VE, Olsen SJ, Bergstrom CT, Dowell SF, Lipsitch M. (2007). Little evidence for genetic susceptibility to influenza A (H5N1) from family clustering data. Emerging infectious diseases, 13(7)

Pitzer VE, Leung GM, Lipsitch M. (2007). Estimating variability in the transmission of severe acute respiratory syndrome to household contacts in Hong Kong, China. American journal of epidemiology, 166(3)

Lipsitch M, Cohen T, Murray M, Levin BR. (2007). Antiviral resistance and the control of pandemic influenza. PLoS medicine, 4(1)

Wang YC, Lipsitch M. (2006). Upgrading antibiotic use within a class: tradeoff between resistance and treatment success. Proceedings of the National Academy of Sciences of the United States of America, 103(25)

Lipsitch M, Robins JM, Mills CE, Bergstrom CT. (2006). Multiple outbreaks and flu containment plans. Science (New York, N.Y.), 312(5775)

Palmer ME, Lipsitch M. (2006). The influence of hitchhiking and deleterious mutation upon asexual mutation rates. Genetics, 173(1)

Mills CE, Robins JM, Bergstrom CT, Lipsitch M. (2006). Pandemic influenza: risk of multiple introductions and the need to prepare for them. PLoS medicine, 3(6)

Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M. (2006). Interference between Streptococcus pneumoniae and Staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. Journal of bacteriology, 188(13)

Trzcinski K, Thompson CM, Gilbey AM, Dowson CG, Lipsitch M. (2006). Incremental increase in fitness cost with increased beta -lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. The Journal of infectious diseases, 193(9)

Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. (2005). CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proceedings of the National Academy of Sciences of the United States of America, 102(13)

Lipsitch M. (2005). Pandemic flu: we are not prepared. MedGenMed : Medscape general medicine, 7(2)

Lipsitch M. (2005). Ethics of rationing the flu vaccine. Science (New York, N.Y.), 307(5706)

Huang SS, Finkelstein JA, Lipsitch M. (2005). Modeling community- and individual-level effects of child-care center attendance on pneumococcal carriage. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 40(9)

Trzciński K, MacNeil A, Klugman KP, Lipsitch M. (2005). Capsule homology does not increase the frequency of transformation of linked penicillin binding proteins PBP 1a and PBP 2x in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy, 49(4)

Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. (2005). Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. PLoS medicine, 2(1)

Trzcinski K, Thompson C, Malley R, Lipsitch M. (2005). Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infection and immunity, 73(10)

Teklehaimanot HD, Schwartz J, Teklehaimanot A, Lipsitch M. (2004). Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia II. Weather-based prediction systems perform comparably to early detection systems in identifying times for interventions. Malaria journal

Mills CE, Robins JM, Lipsitch M. (2004). Transmissibility of 1918 pandemic influenza. Nature, 432(7019)

Lipsitch M, Bergstrom CT. (2004). Invited commentary: real-time tracking of control measures for emerging infections. American journal of epidemiology, 160(6)

Bergstrom CT, Lo M, Lipsitch M. (2004). Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proceedings of the National Academy of Sciences of the United States of America, 101(36)

Cooper B, Lipsitch M. (2004). The analysis of hospital infection data using hidden Markov models. Biostatistics (Oxford, England), 5(2)

Trzciński K, Thompson CM, Lipsitch M. (2004). Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae. Journal of bacteriology, 186(11)

Teklehaimanot HD, Schwatrz J, Teklehaimanot A, Lipsitch M. (2004). Alert threshold algorithms and malaria epidemic detection. Emerging infectious diseases, 10(7)

Lipsitch M, Bergstrom CT, Antia R. (2003). Effect of human leukocyte antigen heterozygosity on infectious disease outcome: the need for allele-specific measures. BMC medical genetics

Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, Gopalakrishna G, Chew SK, Tan CC, Samore MH, Fisman D, Murray M. (2003). Transmission dynamics and control of severe acute respiratory syndrome. Science (New York, N.Y.), 300(5627)

Lipsitch M, Murray MB. (2003). Multiple equilibria: tuberculosis transmission require unrealistic assumptions. Theoretical population biology, 63(2)

McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, Samore MH, Lipsitch M. (2003). Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nature medicine, 9(4)

Trzcinski K, Thompson CM, Lipsitch M. (2003). Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4. Applied and environmental microbiology, 69(12)

Singer RS, Finch R, Wegener HC, Bywater R, Walters J, Lipsitch M. (2003). Antibiotic resistance--the interplay between antibiotic use in animals and human beings. The Lancet. Infectious diseases, 3(1)

Lipsitch M, Singer RS, Levin BR. (2002). Antibiotics in agriculture: when is it time to close the barn door?. Proceedings of the National Academy of Sciences of the United States of America, 99(9)

Lipsitch M, Davis G, Corey L. (2002). Potential benefits of a serodiagnostic test for herpes simplex virus type 1 (HSV-1) to prevent neonatal HSV-1 infection. Sexually transmitted diseases, 29(7)

Lipsitch M, Sousa AO. (2002). Historical intensity of natural selection for resistance to tuberculosis. Genetics, 161(4)

Lipsitch M, Samore MH. (2002). Antimicrobial use and antimicrobial resistance: a population perspective. Emerging infectious diseases, 8(4)

Lipsitch M. (1997). TRANSMISSION RATES AND HIV VIRULENCE: COMMENTS TO MASSAD. Evolution; international journal of organic evolution, 51(1)

Lipsitch M, Siller S, Nowak MA. (1996). THE EVOLUTION OF VIRULENCE IN PATHOGENS WITH VERTICAL AND HORIZONTAL TRANSMISSION. Evolution; international journal of organic evolution, 50(5)

Lipsitch M, Herre EA, Nowak MA. (1995). HOST POPULATION STRUCTURE AND THE EVOLUTION OF VIRULENCE: A "LAW OF DIMINISHING RETURNS". Evolution; international journal of organic evolution, 49(4)